Johns Hopkins researchers suggest that treating refractory dermatomyositis with a JAK inhibitor may improve calcinosis. Based on 3 case reports, who had either NXP2 or TIF-1γ refractory DM, all improved their skin, muscle dz and calcinosis. https://t.co/P5k5y0HS6A